Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Baclofen. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABBR2 known ✓ | O75899 | 8/20 | 1.00 |
| ▸ | GABBR1 known ✓ | Q9UBS5 | 8/20 | 1.00 |
| ▸ | LMNA | P02545 | 3/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 3/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 2/20 | 1.00 |
| ▸ | THRB | P10828 | 2/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 2/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 2/20 | 1.00 |
| ▸ | MEN1 | O00255 | 2/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 2/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 1.00 |
| ▸ | NFKB1 | P19838 | 1/20 | 1.00 |
| ▸ | DRD3 | P35462 | 1/20 | 1.00 |
| ▸ | BLM | P54132 | 1/20 | 1.00 |
| ▸ | TSHR | P16473 | 1/20 | 1.00 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Arbaclofen SCHEMBL351220 | 1.00 | GABBR2 (1.00) | GABBR2GABBR1LMNACYP2C9CYP1A2 | |
| Baclofen SCHEMBL5556250 | 1.00 | GABBR2 (1.00) | GABBR2GABBR1LMNACYP2C9CYP1A2 | |
| Baclofen SCHEMBL19333 | 1.00 | GABBR2 (1.00) | GABBR2GABBR1LMNACYP2C9CYP1A2 | |
| Baclofen SCHEMBL656539 | 0.98 | GABBR2 (0.96) | GABBR2GABBR1LMNACYP2C9CYP1A2 | |
| Arbaclofen SCHEMBL1417519 | 0.98 | GABBR2 (0.96) | GABBR2GABBR1LMNACYP2C9CYP1A2 | |
| Baclofen SCHEMBL4915007 | 0.98 | GABBR2 (0.96) | GABBR2GABBR1LMNACYP2C9CYP1A2 | |
| Baclofen SCHEMBL3004536 | 0.96 | GABBR2 (0.93) | GABBR2GABBR1LMNACYP2C9CYP1A2 | |
| Baclofen SCHEMBL20815463 | 0.96 | GABBR2 (0.93) | GABBR2GABBR1LMNACYP2C9CYP1A2 | |
| Arbaclofen SCHEMBL2996117 | 0.96 | GABBR2 (0.93) | GABBR2GABBR1LMNACYP2C9CYP1A2 | |
| Baclofen SCHEMBL22352888 | 0.93 | GABBR2 (0.87) | GABBR2GABBR1LMNACYP2C9CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 28286 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026106917-A1 | EDIBLE TRANSMUCOSAL DRUG DELIVERY METHOD USING AN INTERMEDIATE CAPSULE AS A TEMPORARY VESSEL | BioPhysics Pharma, Inc. (US) | 2026-05-21 | — | — | WO | claimed |
| CN-114008013-B | Treatment of CNS disorders with sleep disorders | 哥本哈根大学 | 2026-05-15 | — | — | CN | claimed |
| EP-4736841-A1 | A MUCOADHESIVE LAYER FOR BUCCAL ADMINISTRATION OF AN ACTIVE PHARMACEUTICAL INGREDIENT | IQ medical GmbH (DE) | 2026-05-06 | — | — | EP | claimed |
| US-20260115375-A1 | MULTI-FLUID DELIVERY METHOD AND SYSTEM | MCNEER RICHARD (US) | 2026-04-30 | — | — | US | claimed |
| US-20260115140-A1 | COMPOSITIONS FOR ENHANCED MUCOSAL PENETRATION | SHIN NIPPON BIOMEDICAL LABORATORIES LTD (JP) | 2026-04-30 | — | — | US | claimed |
| US-20260115161-A1 | 2-HYDROXY-OCTADECENE-9-CIS-OATE FOR USE IN THE TREATMENT OF ONCOLOGICAL PATHOLOGIES AND NEUROPATHIC PAIN | LAMINAR PHARMACEUTICALS S A (ES) | 2026-04-30 | — | — | US | claimed |
| US-12605345-B2 | Transdermal drug delivery system | BioPhysics Pharma, Inc. (US) | 2026-04-21 | — | — | US | claimed |
| EP-4725506-A2 | THE PEPTIDOMIMETIC COMPOUND (R)-2-AMINO-N-((S)-L-(((S)-5-AMINO-L-(3-BENZYL-1,2,4-OXADIAZOL-5-YL)PENTYL)AMINO)-3-(4-HYDROXY-2,6-DIMETHYLPHENYL)-1-OXOPROPAN-2-YL)-5-GUANIDINOPENTANAMIDE FOR USE IN THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS | Stealth BioTherapeutics Inc. (US) | 2026-04-15 | — | — | EP | claimed |
| EP-4719476-A1 | COMPOSITIONS FOR ENHANCED MUCOSAL PENETRATION | Shin Nippon Biomedical Laboratories, Ltd. (JP) | 2026-04-08 | — | — | EP | claimed |
| US-12594388-B2 | Device to deliver a predetermined amount of a substance to a natural orifice of the body | APTARGROUP, INC. (US) | 2026-04-07 | — | — | US | claimed |
| EP-0307904-A1 | Covered sustained-release forms | CIBA-GEIGY AG (CH) | 1989-03-22 | — | — | EP | claimed |
| US-4780463-A | CONTAINING PROPIONIC ACID COMPOUNDS | ANALGESIC ASSOCIATES (US) | 1988-10-25 | — | — | US | claimed |
| EP-0205492-A1 | ANALGESIC, ANTI-INFLAMMATORY AND SKELETAL MUSCLE RELAXANT COMPOSITIONS | SUNSHINE, Abraham (US) | 1986-12-30 | — | — | EP | claimed |
| WO-1986003681-A1 | ANALGESIC, ANTI-INFLAMMATORY AND SKELETAL MUSCLE RELAXANT COMPOSITIONS | SUNSHINE ABRAHAM | 1986-07-03 | — | — | WO | claimed |
| EP-0179583-A1 | A system for enhancing the water dissolution rate and solubility of poorly soluble drugs | MERCK & CO. INC. (US) | 1986-04-30 | — | — | EP | claimed |
| EP-0147780-A2 | Drug delivery device | MERCK & CO. INC. (US) | 1985-07-10 | — | — | EP | claimed |
| US-4508715-A | DOPAMINE ANTAGONISTS;OVERDOSE TREATMENT | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 1985-04-02 | — | — | US | claimed |
| EP-0105361-A1 | ANTAGONISM OF CENTRAL NERVOUS SYSTEM DRUGS BY THE ADMINISTRATION OF 4-AMINOPYRIDINE ALONE OR IN COMBINATION WITH OTHER DRUGS | THE UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 1984-04-18 | — | — | EP | claimed |
| WO-1983003541-A1 | ANTAGONISM OF CENTRAL NERVOUS SYSTEM DRUGS BY THE ADMINISTRATION OF 4-AMINOPYRIDINE ALONE OR IN COMBINATION WITH OTHER DRUGS | UNIV GEORGIA RES FOUND (US) | 1983-10-27 | — | — | WO | claimed |
| US-4126684-A | 4-AMINO-3-P-HALOPHENYLBUTYRIC ACIDS AND THEIR DERIVATIVES USED IN THE CONTROL OF NARCOTIC ABUSE | CIBA-GEIGY CORPORATION (US) | 1978-11-21 | — | — | US | claimed |